



# COVID-19 Provider Update

Wednesday, October 20, 2021



# Population Coverage: As of October 19

Age range	% of Population	CT Population	At least one dose		Fully vaccinated		Third doses		Total Doses Administered
			Number	%	Number	%	Number	%	
12+	87%	3,105,947	2,580,195	83.1%	2,387,510	76.9%	145,543	4.7%	4,936,468
16+	82%	2,929,347	2,456,765	83.9%	2,279,137	77.8%	145,478	5.0%	4,704,610
18+	80%	2,837,847	2,383,997	84.0%	2,212,534	78.0%	145,418	5.1%	4,565,228
35+	57%	2,047,745	1,807,289	88.3%	1,696,971	82.9%	140,906	6.9%	3,521,545
45+	45%	1,620,604	1,455,281	89.8%	1,373,627	84.8%	135,481	8.4%	2,875,762
55+	32%	1,143,699	1,062,788	92.9%	1,004,855	87.9%	127,507	11.1%	2,136,625
65+	18%	630,244	597,663	94.8%	562,213	89.2%	110,905	17.6%	1,252,898
75+	8%	277,425	255,761	92.2%	239,664	86.4%	54,376	19.6%	543,704

Data as reported to CT DPH Immunization Information System (IIS) CT WiZ.  
 All ages estimate includes 172 people with unknown age



# Age coverage: Specific age groups

*Doses Reported by 10/19/2021*

Age Range	% of Population	CT Population	At least one dose		Fully vaccinated		Third doses		Total Doses Administered
			Number	%	Number	%	Number	%	
12-15	5%	176,600	123,430	69.9%	108,373	61.4%	65	0.0%	231,858
16-17	3%	91,500	72,768	79.5%	66,603	72.8%	60	0.1%	139,382
18-24	10%	342,073	239,587	70.0%	212,271	62.1%	820	0.2%	431,563
25-34	13%	448,029	337,121	75.2%	303,292	67.7%	3,692	0.8%	612,120
35-44	12%	427,141	352,008	82.4%	323,344	75.7%	5,425	1.3%	645,783
45-54	13%	476,905	392,493	82.3%	368,772	77.3%	7,974	1.7%	739,137
55-64	14%	513,455	465,125	90.6%	442,642	86.2%	16,602	3.2%	883,727
65-74	10%	352,819	341,902	96.9%	322,549	91.4%	56,529	16.0%	709,194
75-84	5%	186,095	180,633	97.1%	169,241	90.9%	41,170	22.1%	387,132
85+	3%	91,330	75,128	82.3%	70,423	77.1%	13,206	14.5%	156,572
<b>Grand Total</b>		<b>3,565,287</b>	<b>2,580,367</b>	<b>72.4%</b>	<b>2,387,601</b>	<b>67.0%</b>	<b>145,543</b>	<b>4.1%</b>	<b>4,936,719</b>

\*At least one dose includes individuals who have received one dose of Pfizer, Moderna, or J&J

\*\*Fully vaccinated includes individuals who received one dose of J&J, two doses of Moderna, or two doses of Pfizer.

Total excludes 172 people with unknown age

# Pfizer Age Expansion to 5-11

**On November 2, ACIP voted unanimously to recommend the Pfizer COVID-19 vaccine for children ages 5-11. The recommendation has been posted to the CDC [webpage](#).**

Doses that were pre-ordered have begun to ship and the first wave of doses have already been delivered to many providers.

Pre-orders for pediatric Pfizer accounted for just over 50% of the 96,000 doses allocated to CT.

Orders for the week of 11/8 should be requested via email. As of 11/2, orders placed in the portal will be filled for the week of 11/15 as part of the normal weekly cadence.

**Orders may be placed in the CoVP [ordering portal](#).**

**Please note the dates of distribution at the top of the page when placing your order.**

**Beginning November 9, the minimum order for direct delivery of pediatric Pfizer will be 100 doses.**

## Pfizer Age Expansion to 5-11 (continued)

- Per the EUA, the pediatric formulation will have a shelf life of 12 hours after dilution.
- Many people have asked about 5/8” needs for pediatric products. CDC has reiterated that the pediatric ancillary kits will only contain 1” needs to facilitate IM administration at this time.
- Pediatric Pfizer vaccine does not have expiration dates printed on the boxes and vials. The date listed is the manufacture date. The total shelf-life for product stored in ultra-cold units is 6 months from the manufacture date per the EUA. Documentation accompanying the vaccines lists the vaccine expiration. CDC is preparing a communication with additional information.

# CDC COCA Call

## Pediatric COVID-19 Vaccines: CDC's Recommendations for COVID-19 Vaccine Primary Series in Children 5-11 years old



- **Overview:** CDC will provide an overview of its recommendations and clinical considerations for administering COVID-19 vaccination primary series in children aged 5-11 years old.

[https://emergency.cdc.gov/coca/calls/2021/callinfo\\_110421.asp](https://emergency.cdc.gov/coca/calls/2021/callinfo_110421.asp)



## Pfizer-BioNTech COVID-19 Vaccines

**PRELIMINARY – SUBJECT TO CHANGE PENDING REGULATORY GUIDANCE AND AUTHORIZATION/APPROVAL**

Description	Current Adult/Adolescent Formulation (1170 and 450 packs)	Future Pediatric Formulation
	Dilute Prior to Use	Dilute Prior to Use
Age Group	12 years and older	5 to <12 years**
Vial Cap Color	PURPLE 	ORANGE 
Dose	30 mcg	10 mcg
Injection Volume	0.3 mL	0.2 mL
Fill Volume (before dilution)	0.45 mL	1.3 mL
Amount of Diluent* Needed per Vial	1.8 mL	1.3 mL
Doses per Vial	6 doses per vial (after dilution)	10 doses per vial (after dilution)
<b>Storage Conditions</b>		
ULT Freezer (-90°C to -60°C)	9 months	6 months
Freezer (-25°C to -15°C)	2 weeks	N/A
Refrigerator (2°C to 8°C)	1 month	10 weeks

**Q: Can the current adult/adolescent formulation (purple cap) be used to vaccinate children 5 to <12 years old once the vaccine is authorized for this age group?**

**A: No.** For children under 12 years of age, you cannot use the current formulation and will need to use the future pediatric (orange cap) formulation.

**Purple Cap** – Adult/Adolescent: Authorized only for aged 12 years and older



**Orange Cap** – Pediatric: Future authorization for aged 5- to 12 years. A separate vaccine formulation specific for a 10mcg dose will be introduced.



**NOTE:** Use of the current adult/adolescent formulation (purple cap) to prepare doses for children 5 to <12 years would result in an injection volume for the 10mcg dose of 0.1mL, which is both generally considered too small for typical IM injections and has not been studied.

\*Diluent: 0.9% sterile Sodium Chloride Injection, USP (non-bacteriostatic; DO NOT USE OTHER DILUENTS

\*\*The vaccine is currently under emergency use authorization review by the Food and Drug Administration (FDA) for children 5 to <12 years old



# Thank you!

Thank you for everything you are doing to support our pediatric COVID vaccine roll-out!

A “Call to Action” from Commissioner Manisha Juthani was sent to pediatric practices across CT

This outlined important ways that all providers – especially pediatricians – can support the roll-out.

- Recommend COVID vaccines to your patients and families – *you are the trusted provider*
- Offer COVID vaccines in your offices
- Know how to help families navigate to other local practices or pharmacies if needed



Manisha Juthani, MD  
Commissioner

Ned Lamont  
Governor  
Susan Bysiewicz  
Lt. Governor

Dear Connecticut Pediatricians,

I am writing to you at an exciting and important moment. This week, we expect to receive Centers for Disease Control and Prevention (CDC) authorization and recommendation for the Pfizer COVID-19 vaccine for children ages 5 through 11. Given your commitment to providing quality care to children and families and considering all that you have weathered throughout the pandemic, I know that this is a significant moment for you.

We want to ask for your help and support in enabling your patients to access the pediatric COVID-19 vaccine. Specifically, we are asking you to recommend this vaccine to your patients and families as recommended by the CDC, to offer the vaccine in your offices, and to help guide patients to other vaccine administration locations if you are not offering the vaccine in your office.

#### Your recommendation to vaccinate against COVID-19

Research consistently shows that a provider’s recommendation to vaccinate is the single most influential factor in parents’ decisions to vaccinate their children. You are a trusted source of information, advice, and reassurance.

I ask that you use all the tools at your disposal to help families and individuals make an informed choice about receiving a COVID-19 vaccine. Outreach strategies include sending emails, placing outbound phone calls, and making sure that you counsel every patient and family you see during office visits or telehealth calls about the importance of getting vaccinated.

The CDC has published information for pediatricians, and we expect these resources to be updated during the next week after the final recommendations for children 5-11 are released:

- [How to talk to parents about COVID-19 vaccination](#)
- [COVID-19 Vaccines for Children and Teens](#)

#### Your COVID-19 vaccine delivery

Hundreds of pediatricians and practices across the State are stepping up to offer COVID-19 vaccines for children. For those of you who have not yet completed enrollment as COVID-19 vaccine providers, I want to encourage you to do so. As a reminder, the Pfizer COVID-19 vaccine for children ages 5 through 11 can be stored in the refrigerator for up to 10 weeks, so the storage and handling burden associated with the initial adult Pfizer vaccine roll-out should be significantly alleviated.



# Booster Updates

## mRNA Recipients Booster

For individuals who received a Pfizer-BioNTech or Moderna COVID-19 vaccine, the following groups are eligible for a booster shot at 6 months or more after their initial series:

- 65 years and older
- Age 18+ who live in [long-term care settings](#)
- Age 18+ who have [underlying medical conditions](#)
- Age 18+ who work or live in [high-risk settings](#)

## J&J Booster

All individuals who received a J&J vaccine should receive a booster two months or more after their first dose.

## “Mix & Match”

Both the Food and Drug Administration (FDA) and CDC support individuals to receive a booster dose that is a different vaccine type than they originally received for their primary series if they choose. CDC’s [recommendations](#) now allow for this type of mix and match dosing for booster shots.

**Individuals who are moderately/severely immune compromised and received J&J as their primary dose and choose to receive Moderna should be given the booster dose as approved by FDA/CDC.**

**Vaccinating the *unvaccinated* is still a top priority.**

# Please issue clear recommendations for your patients

**65 and older?**

Get a booster!

**Received J&J?**

Get a booster!

**Other people  
18-64**

You are likely eligible for a booster. Eligible individuals include:

- People with underlying medical conditions, such as being overweight, smoking, having Asthma, Diabetes, high blood pressure, COPD, or mental health disorders
- People who frequently come into contact with strangers or members of the public in their work or living situation

*The choice is yours, considering your individual risk & benefit*

# Additional Booster Information

## Material Updates for Boosters

New Standing Orders have been posted for [Moderna](#), [Janssen](#), and [Pfizer](#) to include language regarding booster doses.

An updated [Quick Reference Guide](#) is also available.

## Updated: Clinical Guidelines for Moderately to Severely Immunocompromised People

CDC's clinical guidelines have been recently updated. Moderately to severely immunocompromised people aged 18 years and older who received a 2-dose mRNA primary series and an additional mRNA additional dose (3 total mRNA vaccine doses) are eligible for a single COVID-19 booster dose (Pfizer-BioNTech, Moderna, or Janssen) at least 6 months after completing their third mRNA vaccine dose.

# Moderna: Use of Vial Adaptors or Spikes

Use of vial adaptors or spikes are not recommended by either the CDC or U.S. The risk of contaminating the vaccine is too great. Unlike many vaccines, COVID-19 vaccines do not contain a preservative, which increases the risk for potential contamination.

Info can be found in the USP COVID-19 Vaccine Toolkit at [www.usp.org/covid-19/vaccine-handling-toolkit](http://www.usp.org/covid-19/vaccine-handling-toolkit) (page 4).

“Refrain from using transfer devices (e.g., mini spikes, dispensing pins, adaptors, etc.) or using one needle to prepare multiple syringes due to potential loss of vaccine in dead space or damage to the stopper and loss of integrity of the vial.”

*Q: Is it acceptable to leave a needle inserted in the septum of a vial for multiple vaccine draws? A: No. A needle should not be left inserted into a vial septum for multiple uses. This provides a direct route for microorganisms to enter the vial and contaminate the fluid.* [Medication Preparation Questions | Injection Safety | CDC](#)

# CDC Science Brief: SARS-CoV-2 Infection-induced and Vaccine-induced Immunity

- **Call to Action:** CDC recommends all eligible people be vaccinated against COVID-19 as soon as possible, including unvaccinated people who were previously infected with the virus that causes COVID-19.
- The data demonstrate that vaccination can provide a higher, more robust, and more consistent level of immunity to protect people from COVID-19 than infection alone

<https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/vaccine-induced-immunity.html>

## Science Brief: SARS-CoV-2 Infection-induced and Vaccine-induced Immunity

Updated Oct. 29, 2021      Print

This brief provides an overview of the current scientific evidence regarding infection-induced and vaccine-induced immunity, including both peer-reviewed and preprint publications, as well as unpublished CDC data. Although comprehensive, it is neither a formal systematic review nor meta-analysis. New data continue to emerge, and recommendations will be updated periodically, as needed.

Recovery from many viral infectious diseases is followed by a period of infection-induced immunologic protection against reinfection. This phenomenon is widely observed with many respiratory viral infections, including both influenza and the endemic coronaviruses, for which acquired immunity also wanes over time making individuals susceptible to reinfection.

CDC continues to recommend COVID-19 vaccination for all eligible persons, including those who have been previously infected with SARS-CoV-2.

### On This Page

[Executive Summary](#)

[Background](#)

[Immune Response to Infection and Vaccination](#)

[Correlation of Immune Response Metrics to Protection](#)

[Immune Response Kinetics and Duration of Protection](#)

[Impact of Variants on Infection- and Vaccine-induced Immunity](#)

[Comparison of Infection- and Vaccine-induced Immune Responses](#)

[Vaccine-induced Immune Responses after Previous Infection](#)

[Limitations](#)

[Conclusions](#)

[References](#)



# CT WiZ/VAMS Update

# Transition to CDC Vaccine Finder Moderna Inventory and Reporting QR Codes Bitly Links

Version 0.1  
10/29/2021

# Transition from CT Vaccine Finder to Vaccines.gov

- Ensure COVID-19 vaccination clinics are registered through VaccineFinder
- Complete daily inventory reporting to VaccineFinder for each COVID-19 vaccination clinic
- Make your clinics visible on Vaccines.gov (Optional)
- For support, email  
[CARS\\_HelpDesk@cdc.gov](mailto:CARS_HelpDesk@cdc.gov)








# Moderna Inventory Adjustment in CT WiZ

Primary (0.5mL) and booster (0.25 mL) doses of Moderna are administered from the same multi-dose vial of 10 or 14 doses. Your inventory on-hand will need to be adjusted per vial based on how many additional doses were administered. Vaccine wastage will also need to be made per vial.

- In CT WiZ, select Inventory – Vaccines – On-Hand – select Actions – select Adjustment:
  - select the *new* Reason code: **Dose Count Variance Multi-Dose Vial** and
  - enter the **Doses Adjusted** (*as whole doses*)
- **CT WiZ User Interface:** document the correct booster dosage administered in CT WiZ:
  - Find the patient – select Action – Add Vaccine – Create And Administer – Change **Dosage field to 0.25**
- **EHR vendors/senders:** please be sure to include the correct dosage volume (primary 0.5mL or add in the booster 0.25 mL) to be reported from your Electronic Health Record (EHR) to CT WiZ.

# Inventory Adjustments in CT WiZ:

1. Go to Vaccines/Inventory/On-hand
2. Select Actions/select Adjustment next to the lot # you need to increase
3. Select Reason code: **Dose Count Variance Multi-Dose Vial**
4. Enter the **Doses Adjusted** (in whole doses)
5. Enter the date and time
6. Select create



The screenshot shows a form titled "Add" with several fields. The "Reason" field is a dropdown menu that is currently open, displaying a list of options. The option "DOSE COUNT VARIANCE MULTI-DOSE VIAL" is highlighted in grey, and a red arrow points to it from the right. The other options in the dropdown are: CVP - OTHER, ADD INITIAL INVENTORY, CVP - BORROWING VACCINE, CVP - OPTED OUT PATIENTS, CVP - TRANSFER TO OFFLINE CLINIC, EXTRA, PRIVATE - BROKE VIAL, and PRIVATE - EXPIRED. Below the dropdown, there are input fields for "Date/Time", "Inventory Location", "Vaccine | Mfg | NDC", "Lot Number", "Expiration Date", "Funding Source", "Doses On-Hand", "Modification", "Doses Adjusted", "Container Id", and "Comments".

# Moderna 14 and 10 dose vial Wastage Tables

The tables on the next slide can assist you with determining the amount of waste to report in CT WiZ, in vials, of Moderna 14 or 10 when administering a combination of primary (0.5mL) and booster (0.25mL) doses.

- Number of full doses administered (primary series) listed on horizontal axis.
- Number of booster doses listed on vertical axis.
- Identify the appropriate line for each type of doses administered from a single vial.
- The intersection of those lines represents the number of doses wasted.
- If your intersection lands within the green field, no wastage occurred, and no reporting is necessary.
- **Tip:** When administering vaccines, do not forget to track which type of dose (primary or booster) was extracted from each vial.



# Moderna 14 and 10 dose vial Wastage Tables

**Modern 14 Wastage Table**

Full doses \ Half Doses	0	1	2	3	4	5	6	7	8	9	10	11	12	13
0	14	13	12	11	10	9	8	7	6	5	4	3	2	1
1	13	12	11	10	9	8	7	6	5	4	3	2	1	0
2	12	11	10	9	8	7	6	5	4	3	2	1	0	
3	11	10	9	8	7	6	5	4	3	2	1	0		
4	10	9	8	7	6	5	4	3	2	1	0			
5	9	8	7	6	5	4	3	2	1	0				
6	8	7	6	5	4	3	2	1	0					
7	7	6	5	4	3	2	1	0						
8	6	5	4	3	2	1	0							
9	5	4	3	2	1	0								
10	4	3	2	1	0									
11	3	2	1	0										
12	2	1	0											
13	1	0												
14	0													
15														
16														
17														
18														
19														
20														

Green Area = No Waste Reported

**Moderna 10 Dose Vial Wastage Table**

Full doses \ Half Doses	0	1	2	3	4	5	6	7	8	9	10
0	10	9	8	7	6	5	4	3	2	1	0
1	9	8	7	6	5	4	3	2	1	0	
2	8	7	6	5	4	3	2	1	0		
3	7	6	5	4	3	2	1	0			
4	6	5	4	3	2	1	0				
5	5	4	3	2	1	0					
6	4	3	2	1	0						
7	3	2	1	0							
8	2	1	0								
9	1	0									
10	0										
11											
12											
13											
14											
15											
16											
17											
18											
19											
20											

Green Area = No Waste Reported


# Smart Health Card

**COMING SOON**


1st Dose COVID-19	COVID-19 mRNA (PFR) E654T3	02/01/2021	PARENT RECORD (PROLD)
2nd Dose COVID-19	COVID-19 mRNA (PFR) RT674F	02/22/2021	PARENT RECORD (PROLD)
Other	COVID-19 mRNA (PFR) T85GH4	10/05/2021	PARENT RECORD (PROLD)
Other		-- / -- / --	



## Digital COVID-19 Vaccination Record



- This SMART Health Card is a Digital COVID-19 Vaccination Record (<https://smarthealth.cards/>)
- Keep a copy or share this with a trusted organization by letting them scan the 2D barcode (QR code) on your paper or phone screen
- Downloaded/Printed on 10/14/2021 at 10:34:00AM
- You may not misuse, modify, alter, amend or remove any of the content on this card. Misuse of this card in any way is expressly prohibited and may constitute a criminal offense punishable by imprisonment.



---

[ct.gov/izrecord](http://ct.gov/izrecord) (CT WiZ Public Portal)

[ct.gov/ctwizschoolnurses](http://ct.gov/ctwizschoolnurses)

[ct.gov/allaboutctwiz](http://ct.gov/allaboutctwiz)

[ct.gov/ctwiztraining](http://ct.gov/ctwiztraining)

[ct.gov/ctwizaccount](http://ct.gov/ctwizaccount) (To request a username)

[ct.gov/immunizationlawsandregs](http://ct.gov/immunizationlawsandregs)



# CT WiZ/VAMS Office Hours

## [CT WiZ/VAMS Live Helpdesk Office Hours](#)

- Join Via Microsoft Teams
- Tuesdays 9:00 – 10:00
- Join anytime during office hours to ask a question



**VAMS** Vaccine Administration  
Management System



# Question and Answers

To ask a question, please raise your hand using the hand icon on your screen, type your question in the chat box or if you are on the phone press \*6 to unmute yourself.

If you have additional questions after the meeting, please feel free to email them to [DPH.Immunizations@ct.gov](mailto:DPH.Immunizations@ct.gov)

You can fill out a help desk ticket by visiting <https://dph-cthelpdesk.ct.gov/Ticket>